exploring advantages to third-generation tkis in lung cancer
Published 5 years ago • 359 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
1:18
exploring neoadjuvant egfr-tkis in lung cancer
-
2:36
second- and third-generation tkis in egfr-mutated nsclc
-
4:48
third-generation egfr inhibitors in nsclc
-
0:53
ramalingam compares third generation egfr tki osimertinib to older agents in nsclc
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
1:24
egfr tkis excite treatment landscape of egfr-mutant lung cancers
-
3:07
third generation egfr tkis for acquired resistance
-
6:14
third-generation egfr inhibitors in nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
3:12
egfr-tki therapy in advanced nsclc
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
4:17
grace targeted therapies lung cancer 2021 - utility & benefit 3rd generation tki after progression
-
2:51
early results from a 3rd gen egfr-tki in advanced nsclc
-
2:26
additional egfr-tki therapy research in nsclc
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
1:02
examining data for osimertinib in egfr lung cancer
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
20:34
2021 west oncology | lung cancer | egfr mutation therapy resistance and adcs and trop2